Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
Namandjé N. Bumpus Principal Deputy Commissioner at U.S. Food And Drug Administration (fda) | Official website
This is an increase over the number of companies cited in the previous year.
The citations in the county include:
- The labels of the medical device(s) do not bear a unique device identifier (UDI) that meet the requirements of 801 Subpart B and 21 CFR 830.
- Risk analysis was not performed.
- Procedures for corrective and preventive action have not been adequately established.
The company cited should take a voluntary action to correct its managing operations.
The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.
The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.
Company Name | Area of Business | Inspection Date | Issue Cited |
---|---|---|---|
Aquila Corporation | Devices | 12/07/2023 | Label to bear a unique device identifier |
Aquila Corporation | Devices | 12/07/2023 | Design Validation - Risk analysis not performed/inadequate |
Aquila Corporation | Devices | 12/07/2023 | Lack of or inadequate procedures |
Aquila Corporation | Devices | 12/07/2023 | Lack of or inadequate complaint procedures |